肝胆肿瘤分子诊断临床应用专家共识.

In hepatobiliary carcinoma,serologic and histologic biomarkers including proteins and genes have been recommended and categorized for cancer diagnosis,targeted therapy and immunotherapy regimen selection,as well as prognostic prediction at different levels. To standardize the application of molecular biomarkers in clinical diagnosis,therapeutic evaluation,and prognosis prediction of primary hepatobiliary carcinoma,the specialist committee has summarized the current well studies biomarkers with clinical significance in both serum and tumor tissue as well as provided professional agreements on their potential utilization in this consensus. Moreover,we have made recommendations on standards for laboratory detection,technical operation,data analysis,result interpretation,clinical report,and the whole-process quality management in serological,histopathological detection and next-generation sequencing. According to these,the committee aims to offer clinical staffs with scientific and practical references and guidance to achieve better personalized treatment decisions from these up-to-date knowledges of molecular diagnosis on hepatobiliary carcinoma. [ABSTRACT FROM AUTHOR]